Field Medical Inc – Weekly Recap

Field Medical Inc spent the week showcasing its investigational FieldForce pulsed field ablation system across multiple research presentations at the HRS2026 electrophysiology conference in Chicago. The company highlighted data spanning both atrial and ventricular arrhythmias, including atrial fibrillation and complex ventricular tachycardia cases.

Poster sessions featured large-volume ventricular ablation using an instantaneous ablation system and high-voltage pulsed field ablation strategies for redo ventricular tachycardia in nonischemic cardiomyopathy patients. Several studies were investigator-led, underscoring Field Medical’s focus on clinical collaborations to expand the evidence base for its technology.

Field Medical also marked the two-year anniversary of its first-in-human case, positioning that milestone as the foundation of its pulsed field ventricular tachycardia program. The company referenced progress in its VCAS trial and a next phase of development, suggesting continued investment in research and development and clinical validation activities.

Around HRS2026, the company emphasized growing thought-leader engagement, with CEO Mark A. Turco, M.D., scheduled for a Speed Talk on electrophysiology innovation. In addition, electrophysiologist Vivek Reddy, M.D., is presenting on high-voltage, focal force-sensing pulsed field ventricular tachycardia ablation, further raising the profile of Field Medical’s platform.

Despite this visibility, the FieldForce PFA System remains an investigational device limited by U.S. law to investigational use, reinforcing Field Medical’s pre-revenue status. Any potential commercial impact depends on future trial results and regulatory milestones, although expanding clinical data and conference exposure may bolster the company’s standing in the competitive medtech electrophysiology market.

Overall, the week underscored Field Medical’s strategy of pairing intensive clinical data generation with targeted presence at major cardiology meetings, laying groundwork that could influence its longer-term regulatory and commercialization trajectory.